Systemic Steroids
Phase 2Small molecule
Systemic Steroids is one of 51 small molecule programs targeting Sudden Sensorineural Hearing Loss. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
103 competitors in Vitiligo
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Opzelura
PfizerPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Povorcitinib
IncytePhase 3
Olumiant
Eli LillyPhase 2
Otezla
AmgenPhase 2
Saphnelo
AstraZenecaPhase 2
Scenesse
CClinuvel Pharmaceuticals Limited
Phase 2
Kenalog
BBassett Healthcare
Phase 2
Enbrel
IImmunex
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sudden Sensorineural Hearing Loss1 trial
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Unknown status·—·Phase 2·NCT05403229·140 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Systemic Steroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Bordeaux